51 Biggest Movers From Yesterday

Gainers

• Advent Technologies Holdings, Inc. NASDAQ:ADN shares climbed 79.7% to close at $3.63 on Wednesday. Advent Technologies and Hyundai Motor Company entered into technology assessment, sales and development agreement.
• Tufin Software Technologies Ltd. NYSE:TUFN surged 43.1% to close at $12.92 after the company announced it will be acquired by Turn/River Capital for $13 per share in cash.
• Moxian BVI Inc NASDAQ:MOXC gained 39.8% to close at $2.32 on above-average volume.
• Mobiquity Technologies, Inc. NASDAQ:MOBQ surged 29.6% to close at $2.10 after the company announced it has been selected by A-Nation as its data and programmatic advertising provider.
• Newegg Commerce, Inc. NASDAQ:NEGG gained 27.2% to close at $8.66 on above-average volume.
• Alset EHome International Inc. NASDAQ:AEI jumped 24.3% to close at $0.6847. Alset EHome International recently reported FY2021 results with a 22% revenue growth.
• Missfresh Limited NASDAQ:MF gained 23.4% to close at $1.58.
• Team, Inc. NYSE:TISI climbed 22.4% to close at $2.73. Team recently regained compliance with NYSE listing standards.
• Nuvectis Pharma, Inc. NASDAQ:NVCT climbed 18.9% to close at $10.25.
• Enlivex Therapeutics Ltd. NASDAQ:ENLV rose 17.5% to settle at $8.64.
• Fang Holdings Limited NYSE:SFUN gained 17.1% to settle at $4.3927. Fang, in February, appointed Mr. Peng Cui as CFO.
• Icosavax, Inc. NASDAQ:ICVX jumped 16.3% to close at $7.57. Icosavax recently reported Q4 results.
• Concord Medical Services Holdings Limited NYSE:CCM rose 14.9% to close at $1.8962.
• Venator Materials PLC NYSE:VNTR gained 14.6% to close at $1.96 after the company won its $75 million lawsuit against Tronox.
• Sunshine Biopharma, Inc. NASDAQ:SBFM climbed 12.1% to close at $6.29. Sunshine Biopharma announced that two of its newly designed mRNA molecules are effective at destroying cancer cells grown in culture.
• Fresh Vine Wine, Inc. NYSE:VINE gained 12.1% to close at $4.16. Fresh Vine Wine named Ellen Scipta as CFO.
• Sunshine Biopharma, Inc. NASDAQ:SBFM shares rose 12.1% to close at $6.29. Sunshine Biopharma shares jumped 148% on Tuesday after the company announced that two of its designed mRNA molecules are effective at destroying cancer cells grown in culture.
• Smart Sand, Inc. NASDAQ:SND rose 10.1% to close at $4.03.
• Guardion Health Sciences, Inc. NASDAQ:GHSI rose 9.4% to close at $0.2316. Guardion Health Sciences recently reported FY21 loss of $1.04 per share.
• Gogo Inc. NASDAQ:GOGO shares rose 7.6% to close at $20.65. Gogo recently named Sergio Aguirre as President and COO.

Don't forget to check out our premarket coverage here .

Losers

• Nutex Health Inc. NASDAQ:NUTX fell 32.8% to close at $17.90.
• Guardforce AI Co., Limited NASDAQ:GFAI dipped 32.5% to close at $1.14 as the company reported pricing of $10.0 million registered direct offering.
• Velo3D, Inc. NYSE:VLD fell 26.5% to close at $6.33.
• GWG Holdings, Inc. NASDAQ:GWGH dipped 25.1% to close at $2.62.
• Dakota Gold Corp. NYSE:DC fell 21.6% to close at $5.41 after the company was uplifted to NYSE American.
• Forge Global Holdings, Inc. NYSE:FRGE dipped 21.4% to close at $20.60 on below-average volume.
• Integrated Media Technology Limited NASDAQ:IMTE fell 21.4% to close at $20.52. Integrated Media Technology reported distribution agreement on halal products for European Markets.
• Anghami Inc. NASDAQ:ANGH dropped 20.4% to close at $10.67 after jumping around 48% on Tuesday.
• Sensus Healthcare, Inc. NASDAQ:SRTS fell 20.3% to close at $8.78.
• Swvl Holdings Corp. NASDAQ:SWVL dropped 20.1% to close at $6.90.
• Senmiao Technology Limited NASDAQ:AIHS shares fell 19.1% to settle at $1.74. Senmiao Technology reported a 1-for-10 reverse stock split, effective Apr. 6, 2022.
• Hyzon Motors Inc. NASDAQ:HYZN fell 17.4% to close at $5.13 after Canaccord Genuity downgraded the stock from Buy to Hold and lowered its price target from $12 to $6.
• Codex DNA, Inc. NASDAQ:DNAY dropped 16.9% to close at $5.36.
• Celsion Corporation NASDAQ:CLSN fell 16.7% to close at $5.18 after the company announced a $7 million registered direct offering priced at-the-market under Nasdaq rules.
• Greenidge Generation Holdings Inc. NASDAQ:GREE dropped 16.7% to close at $8.95.
• Rhythm Pharmaceuticals, Inc. NASDAQ:RYTM fell 16.3% to close at $9.80. Rhythm Pharmaceuticals will modify its Phase 3 EMANATE and ongoing Phase 2 DAYBREAK trials of setmelanotide in rare genetic diseases of obesity.
• VEON Ltd. NASDAQ:VEON fell 15.8% to settle at $0.5806.
• FreightCar America, Inc. NASDAQ:RAIL fell 14.7% to settle at $5.58. FreightCar America recently reported better-than-expected Q4 EPS and sales results.
• Beam Global NASDAQ:BEEM dipped 14.2% to close at $21.78.
• Nextdoor Holdings, Inc. NASDAQ:KIND fell 13.7% to close at $5.55.
• GBS Inc. NASDAQ:GBS fell 12.4% to close at $1.06.
• Homology Medicines, Inc. NASDAQ:FIXX dropped 11.8% to close at $2.54. Canaccord Genuity maintained Homology Medicines with a Buy and lowered the price target from $19 to $7.
• Sphere 3D Corp. NYSE:ANY fell 11.5% to close at $2.24.
• Reviva Pharmaceuticals Holdings, Inc. NASDAQ:RVPH fell 11.1% to close at $2.16.
• Cano Health, Inc. NYSE:CANO dipped 11.1% to close at $5.59 after Piper Sandler downgraded the stock from Neutral to Underweight and lowered its price target from $8.50 to $5.
• Avis Budget Group, Inc. NASDAQ:CAR fell 10.9% to settle at $246.44 after B of A Securities downgraded the stock from Neutral to Underperform and lowered its price target from $250 to $240.
• TD Holdings, Inc. NASDAQ:GLG fell 10.9% to settle at $0.2820. GLG Life Tech recently reported Q4 results.
• Owlet, Inc. NYSE:OWLT fell 9.3% to close at $4.22.
• Tantech Holdings Ltd NASDAQ:TANH fell 8.6% to close at $0.6081 after surging around 31% on Tuesday. Tantech recently said its subsidiary, Shangchi Automobile Co Ltd, won an additional ten vehicle orders.
• Aterian, Inc. NASDAQ:ATER shares fell 6.6% to close at $3.41. Aterian recently said that Cynthia Williams has joined the Company's Board of Directors.
• Inventiva S.A. NASDAQ:IVA fell 6.3% to close at $11.25. The FDA completed a safety review of Inventiva's IND application and signed off Phase 2 combination trial with its lead drug candidate, lanifibranor.